18 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Adverse Event FrequencyPrimary· 6 months
Number of patients reporting adverse events
Patients experiencing AEs
Group
Value
95% CI
Treatment Arm
11
Placebo Arm
11
Patients who Experienced SAE
Group
Value
95% CI
Treatment Arm
1
Placebo Arm
0
Assess Change of AUC of GLP-1 as a Therapeutic Biomarker for Clinical Response to Fecal Microbiota Transplantation From Baseline to Week 12Secondary· 12 weeks
Fecal Microbiota Transplantation will lead to an increase in short chain fatty acids which will lead to an increase in the metabolic regulator GLP-1
Group
Value
95% CI
Treatment Arm
509.6
± 318.7
Placebo Arm
311.3
± 261
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data was collected over the course 6 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a randomized controlled pilot study to assess the microbiological and clinical impacts of Fecal Microbiota Transplantation (FMT) in patients with obesity. The investigators will prospectively enroll 20 adult patients who are obese (Body Mass Index of 35kg/m2 or higher) after providing written informed consent. The study participants will be randomized 1:1 to either the treatment arm or the placebo arm. The treatment arm will receive an induction FMT with capsules followed by a monthly maintenance dose of oral capsules for 12 weeks total. The placebo group will receive a placebo capsules for induction followed by monthly intake of oral placebo capsules for 12 weeks.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis
· NA
· recruiting
NCT07454408 — Evaluation of the Outcome of Fecal Microbiota Transplantation
· Phase 1, PHASE2
· not yet recruiting
NCT07463248 — PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line
· Phase 2
· not yet recruiting
NCT07042438 — Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Expo
· Phase 2
· recruiting
NCT06744751 — A Study on the Effects of Combined FMT on Gut Microbiota and Eating Disorder Symptoms in AN
· NA
· not yet recruiting
Other recruiting trials for Obesity
Currently open trials in the same condition.
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Other Brigham and Women's Hospital trials
Trials by the same sponsor.
NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder
· Phase 2
· not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE
· suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ...
· NA
· not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
· NA
· not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography
· suspended
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 7 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02741518.